Generation of human induced pluripotent stem cell-derived liver buds with chemically defined and animal origin-free media
Rattachement africain : jp, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Advances in organoid technology have broadened the number of target diseases and conditions in which human induced pluripotent stem cell (iPSC)-based regenerative medicine can be applied; however, mass production of organoids and the development of chemically defined, animal origin-free (CD-AOF) media and supplements are unresolved issues that hamper the clinical applicability of these approaches. CD-AOF media and supplements ensure the quality and reproducibility of culture systems by lowering lot-to-lot variations and the risk of contamination with viruses or toxins. We previously generated liver organoids from iPSCs, namely iPSC-liver buds (iPSC-LBs), by mimicking the organogenic interactions among hepatocytes, endothelial cells (ECs), and mesenchymal cells (MCs) and recently reported the mass production of iPSC-LBs derived entirely from iPSCs (all iPSC-LBs), which should facilitate their large-scale production for the treatment of liver failure. However, in previous studies we used media originating from animals for differentiation except for the maintenance of undifferentiated iPSCs. Therefore, we developed a CD-AOF medium to generate all iPSC-LBs. We first developed a CD-AOF medium for hepatocytes, ECs, and stage-matched MCs, i.e., septum transversum mesenchyme (STM), in 2D cultures. We next generated all iPSC-LBs by incubating individual cell types in ultra-low attachment micro-dimple plates. The hepatic functions of all iPSC-LBs generated using the CD-AOF medium were equivalent to those of all iPSC-LBs generated using the conventional medium both in vitro and in vivo. Furthermore, we found that this CD-AOF medium could be used in several cell culture settings. Taken together, these results demonstrate the successful development of a CD-AOF medium suitable for all iPSC-LBs. The protocol developed in this study will facilitate the clinical applicability of all iPSC-LBs in the treatment of liver diseases.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Generation of human induced pluripotent stem cell-derived liver buds with chemically defined and animal origin-free media
- Date Crossref
- 21/10/2020
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Tokyo The Institute of Medical Science pays non établi dans la noticeUniversité ou école supérieure
-
Yokohama City University Department of Regenerative Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Ajinomoto (Japan) pays non établi dans la noticeEntreprise
-
Cincinnati Children's Hospital Medical Center Center for Stem Cell and Organoid Medicine (CuSTOM) pays non établi dans la noticeÉtablissement de santé
-
Yokohama City University Medical Center pays non établi dans la noticeÉtablissement de santé
-
University of Cincinnati Medical Center pays non établi dans la noticeÉtablissement de santé
-
Research Institute for Bioscience Products and Fine Chemicals pays non établi dans la noticeStructure de recherche
-
University of Cincinnati College of Medicine Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
The Institute of Medical Science — The University of Tokyo, Department of Regenerative Medicine — Yokohama City University et Ajinomoto (Japan), avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.